In a patient whose estimated glomerular filtration rate (eGFR) has decreased from 62 to 45 mL/min/1.73 m², what factors should be evaluated and what management steps should be taken?

Evaluation of eGFR Drop from 62 to 45 mL/min/1.73 m²

This represents a significant decline from CKD stage G2 to G3b, requiring immediate assessment for reversible causes, measurement of albuminuria if not recently done, and consideration of nephrology referral depending on the underlying cause and rate of decline 1, 2.

Immediate Assessment Priorities

1. Determine if This is Acute or Progressive Decline

Calculate the rate of decline to distinguish between acute kidney injury and CKD progression:

• If this occurred over <3 months: likely acute kidney injury requiring urgent evaluation
• If over 1 year: decline of ~17 mL/min/1.73 m² per year—this is rapid progression (>5 mL/min/1.73 m² per year) 1
• If over 2+ years: still concerning but less acute

A decline of 25% or more (which this is: 27% decline) accompanied by a drop in GFR category constitutes "certain drop" and is associated with 5-fold increased risk of ESRD and nearly 2-fold increased mortality risk 1.

2. Check for Reversible Causes Immediately

Examine for:

• Volume depletion: recent diuretic changes, vomiting, diarrhea, poor oral intake
• Medications: NSAIDs, recent ACE inhibitor/ARB initiation or dose increase (>30% drop is expected with these agents) 3, antibiotics (aminoglycosides, vancomycin)
• Urinary obstruction: check for symptoms of prostatic hypertrophy, pelvic masses
• Acute illness: sepsis, heart failure exacerbation, liver disease
• Contrast exposure: recent imaging studies with IV contrast

3. Measure Albuminuria Status NOW

If not measured within the past 3 months, obtain spot urine albumin-to-creatinine ratio (UACR) immediately 1, 4. This is critical because:

• eGFR 45 mL/min/1.73 m² with UACR ≥300 mg/g = very high risk requiring nephrology referral 2
• eGFR 45 mL/min/1.73 m² with UACR 30-299 mg/g = high risk requiring treatment intensification 5
• eGFR 45 mL/min/1.73 m² with UACR <30 mg/g = moderate risk requiring monitoring 5

Staging and Risk Stratification

This patient now has CKD stage G3a (eGFR 45-59 mL/min/1.73 m²) 6, 7. The risk level and management intensity depend entirely on albuminuria:

• Without albuminuria (<30 mg/g): Moderate risk—monitor eGFR and UACR twice yearly 2, 4
• With moderate albuminuria (30-299 mg/g): High risk—monitor 3 times yearly, intensify treatment 2, 4
• With severe albuminuria (≥300 mg/g): Very high risk—monitor 4 times yearly, refer to nephrology 2

Management Algorithm

Step 1: Review Current Medications

• If on ACE inhibitor/ARB: A 30% eGFR drop may be acceptable if initiated recently; repeat creatinine in 2-4 weeks 3
• If on SGLT2 inhibitor: Initial dips >10% are common and associated with long-term benefit; dips >30% warrant volume status review 3
• Stop nephrotoxins: NSAIDs, proton pump inhibitors if possible, aminoglycosides

Step 2: Optimize Blood Pressure and Proteinuria Control

For patients with diabetes and eGFR <60 mL/min/1.73 m²:

• ACE inhibitor or ARB is strongly recommended if UACR ≥300 mg/g 4
• ACE inhibitor or ARB is recommended if UACR 30-299 mg/g 4
• Titrate to maximum approved doses for hypertension unless contraindicated 7

For patients with CKD (with or without diabetes):

• SGLT2 inhibitor is recommended if eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g 4
• Consider SGLT2 inhibitor even with lower albuminuria given proven renoprotection 2, 8

Step 3: Determine Need for Nephrology Referral

Refer to nephrology if any of the following:

• Rapid progression (>5 mL/min/1.73 m² per year decline) 1
• UACR ≥300 mg/g at any eGFR 2
• eGFR <30 mL/min/1.73 m² 2, 4
• Uncertain etiology of kidney disease
• Persistent hematuria or red cell casts
• Refractory hypertension (≥4 agents)
• Persistent hyperkalemia 2

Step 4: Adjust Monitoring Frequency

At eGFR 45-59 mL/min/1.73 m²:

• Measure eGFR and UACR 2-3 times per year depending on albuminuria category 2, 4
• Monitor potassium and creatinine within 2-4 weeks after any medication change 4
• Screen for CKD complications: anemia, bone mineral disease, metabolic acidosis

Step 5: Lifestyle and Comorbidity Management

• Protein intake: Limit to 0.8 g/kg/day if diabetic kidney disease 6
• Glycemic control: Target HbA1c individualized but generally <7% to slow progression 6
• Blood pressure: Target <130/80 mmHg in most patients with CKD 4
• Cardiovascular risk reduction: Statin therapy, smoking cessation 2

Common Pitfalls to Avoid

1. Do not discontinue ACE inhibitor/ARB for creatinine increases <30% unless volume depleted 4
2. Do not assume eGFR fluctuation is benign—a >20% change exceeds expected variability and warrants evaluation 3
3. Do not delay albuminuria testing—it fundamentally changes risk stratification and treatment 1, 4
4. Do not use metformin if eGFR <30 mL/min/1.73 m²; reduce dose if eGFR 30-45 mL/min/1.73 m² 9
5. Do not overlook medication dose adjustments—many drugs require adjustment at eGFR <60 mL/min/1.73 m² 9

Expected Natural History

Without intervention, patients with eGFR in the 45-59 range typically decline at 2-4 mL/min/1.73 m² per year 1. However, with appropriate renoprotective therapy (RAS inhibition, SGLT2 inhibitors), this can be slowed to <1 mL/min/1.73 m² per year 8, 10.